States like Colorado and Maryland are considering implementing prescription drug affordability boards, focusing on limiting health plans' payments for expensive medications. Meanwhile, the Inflation Reduction Act is projected to significantly benefit Medicare enrollees by capping out-of-pocket drug costs at $2,000 starting in 2025, translating to average savings of around $1,500 per enrollee. In Arkansas, this legislation is expected to reduce drug costs and expand insurance coverage for thousands of residents. Indiana also anticipates similar relief as the Biden administration negotiates prices for high-cost drugs, with an emphasis on older adults who face rising healthcare expenses. AARP reports that over 27,000 seniors in Iowa will particularly benefit from these changes, providing critical financial relief for a vulnerable population. However, pharmaceutical companies have expressed concerns that these policies could stifle innovation in drug development.